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Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify
patients who will evolve
Undifferentiated connective tissue disease at risk of SSc (UCTD-risk-
SSc) [1], otherwise referred to as very early-early SSc [2] is a condition
charactherised by Raynaud's phenomenon (RP) and either SSc marker
autoantibodies or distinct capillaroscopic alterations or both [2]. This
condition has been reported to evolve into SSc satisfying ACR/EULAR
criteria [3] in 50% of cases [4]. At present, it remains to be established
how to predict such evolution.
In order to address this topic, 102 UCTD-SSc-risk patients unful-
filling at admission the 2013 ACR/EULAR classification criteria [3]
neither presenting any manifestation indicative of SSc sine scleroderma
[5] were prospectively enrolled from November 1st, 2000 and followed
up, as previously outlined [4] for 1–12 years (median 3 years) to De-
cember 31st, 2017. Out of them, 96 were females; the median age at
admission was 44 years (range 16–73); the median disease duration
from RP was 3 years (range 1–31). At baseline, 72 were IF-ANA posi-
tive; 65 presented a serum SSc marker autoantibody (16 anti-Scl70, 46
anticentromere; 2 anti-Th/To; 1 anti-Pm-Scl); 81, at nailfold videoca-
pillaroscopy, showed megacapillaries only; 3 of them also had avas-
cular areas; 33 were found to have a DLCO<80% of predicted value,
indicative of preclinical lung involvement; 21 an inverted E/A ratio,
indicative of preclinical heart involvement [4]; any of these alterations
being detected in 49.
During follow-up, 46/102 patients evolved to definite SSc. At Cox
regression univariate analysis, a baseline IF-ANA titer ≥1: 320 (HR
9.69; 95% CI 3.01–31.17; p= .0001), anti-Scl-70 positivity (HR 2.92;
95% CI 1.52–5.63; p= .001), ACA positivity (HR 2.27 95% CI
1.23–4.18; p= .008), presence of avascular areas as detected by vi-
deocapillaroscopy (HR 4.45; 95% CI 1.35–14.63; p= .01), and pre-
clinical heart and/or lung involvement (HR 1.91; 95% CI 1.06–3.45;
p= .03) were found to significantly predict evolution to SSc.
Interestingly, none of the 30 ANA-negative patients of the 37 diagnosed
as UCTD-risk-SSc because of the presence of megacapillaries evolved to
definite SSc versus 2 of the 7 ANA-positive patients (p= .03).
Table 1 shows the variables that predicted evolution to definite SSc
and the relative weight that we assigned to each of them on a 10-point
scale depending on the respective β values. Fig. 1 shows the results of
the ROC analysis conducted to identify the score with the highest
sensitivity and specificity. A score > 2.75 predicted evolution to SSc in
patients affected by UCTD-risk-SSc with a sensitivity of 91.3% (<1 of
10 patients who would evolve to SSc would not be captured) and a
73.2% specificity (about 3 of 10 non-evolving patients would be con-
sidered at risk of evolution). Notably, a score of 4.25 (i.e., ANA ≥1:320
plus ACA positivity) had a specificity as high as 100%.
Predicting which patients with UCTD-risk-SSc (very-early SSc) will
evolve to definite SSc has long been a challenge [6]. Actually, given the
lack of definite predictive criteria of evolution to SSc, Bellando Ran-
done and Matucci Cerinic [7] stated that the only feasible clinical
strategy in very early SSc is to enroll patients in a strict follow-up
program to detect early internal organ involvement in “real time”, in
order to start an aggressive therapeutic approach.
Here, we describe a 10-point score based on features that are easily
identified at admission and predicts evolution to full-blown SSc.
Although awaiting validation by studies conducted in other prospective
cohorts, the score identified by us can help clinicians in their everyday
approach to the patient with UCTD-risk-SSc (very early/early SSc).
Table 1
Indipendent predictors of evolution into definite SSc based on multivariate
regression. Relative weight in a 10-point score as derived by the respective
regression coefficienta
Variable Β HR 95% CI P Weight
Anti-Scl70 2.4484 11.57 3.12–42.88 0.0003 3
ANA ≥1:320 1.9359 6.93 1.81–26.51 0.0049 2.75
Avascular areas 1.6166 5.03 1.36–18.59 0.0158 2.25
ACA 1.3672 3.92 1.13–13.59 0.0319 2
a β: regression coefficients; ANA: anti-nuclear antibodies; HR: hazard ratio;
95% CI: 95% confidence interval;ACA: anti-centromere antibodies.
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